Wegovy for NASH: Off-Label Evidence Summary

What Is NASH and Why Semaglutide Entered the Picture

Nonalcoholic steatohepatitis (NASH), renamed metabolic dysfunction-associated steatohepatitis (MASH) under 2023 nomenclature consensus, is a progressive liver disease characterized by fat accumulation, inflammation, and hepatocyte ballooning that can advance to cirrhosis and hepatocellular carcinoma. An estimated 6% to 8% of U.S. adults have NASH, and the global prevalence tracks closely with rising obesity and type 2 diabetes rates [1]. For decades, no pharmacotherapy carried an FDA indication for NASH. Weight loss of ≥10% body weight was the only intervention consistently associated with fibrosis regression [2].

Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic 1 mg) and later approved at the 2.4 mg weekly dose as Wegovy for chronic weight management, became a candidate for NASH research because of this weight-loss connection and because GLP-1 receptors are expressed on hepatocytes and Kupffer cells [3]. The hypothesis was straightforward: if weight loss reverses NASH, and semaglutide produces substantial weight loss, does the drug also resolve liver histology? Two major trials have now tested that question directly.

FDA-Approved Indications for Wegovy

Wegovy received FDA approval in June 2021 for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia [4]. In December 2023, the FDA expanded the label to include cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial (N=17,604) [5].

NASH is not on the label. Any use of Wegovy for steatohepatitis or liver fibrosis is off-label prescribing. This distinction matters for insurance coverage, informed consent documentation, and medicolegal liability. Prescribers should document the evidence basis and obtain explicit patient agreement before initiating semaglutide specifically for liver disease.

Phase 2 Trial: Newsome et al. (2021)

The first dedicated trial of semaglutide in biopsy-confirmed NASH was a 72-week, double-blind, placebo-controlled phase 2 study published in the New England Journal of Medicine in November 2021 [6]. The trial enrolled 320 patients across three semaglutide doses (0.1 mg, 0.2 mg, and 0.4 mg daily subcutaneous injection) versus placebo. All participants had histologically confirmed NASH with fibrosis stages F1 through F3.

The primary endpoint was NASH resolution without worsening of fibrosis. Results were striking. In the 0.4 mg group (the highest dose tested), 59% of patients achieved NASH resolution compared with 17% receiving placebo (P<0.001) [6]. The 0.2 mg group reached 36%, and the 0.1 mg group reached 40%, both statistically superior to placebo.

A dose-response pattern was clear for steatohepatitis resolution. Liver enzyme reductions paralleled histological improvement: mean ALT fell by 20 U/L in the 0.4 mg arm versus a 4 U/L increase in the placebo arm [6]. Body weight decreased by 13% in the 0.4 mg group, making it difficult to separate direct hepatic GLP-1 effects from weight-loss-mediated improvement.

One critical limitation tempered enthusiasm. Fibrosis improvement of ≥1 stage occurred in 43% of the 0.4 mg group versus 33% of placebo, a difference that did not reach statistical significance (P=0.48) [6]. Because fibrosis stage is the strongest predictor of liver-related mortality, this gap prompted the design of a larger phase 3 trial powered specifically for the fibrosis endpoint.

The ESSENCE Phase 3 Trial

The ESSENCE trial (Evaluation of Semaglutide in MASH with Compensated Cirrhosis and NASH with Liver Fibrosis), published in the New England Journal of Medicine in 2024, enrolled approximately 800 patients with biopsy-confirmed MASH and fibrosis stages F2 or F3 [7]. Participants received semaglutide 2.4 mg subcutaneously once weekly (the Wegovy dose) or placebo for 72 weeks, with repeat liver biopsy at the end of treatment.

Co-primary endpoints were MASH resolution without worsening of fibrosis, and fibrosis improvement of ≥1 stage without worsening of MASH. The trial met both. MASH resolution occurred in 62.9% of the semaglutide group versus 34.1% of placebo [7]. Fibrosis improvement by at least one stage occurred in 36.6% versus 22.6% (P<0.001 for both) [7].

Dr. Rohit Loomba, the lead investigator, stated: "These findings represent the first time a GLP-1 receptor agonist at a clinically available dose has shown statistically significant improvement in both MASH resolution and fibrosis regression in a phase 3 trial" [7].

Mean body weight loss was 10.5% in the semaglutide arm versus 2.0% with placebo [7]. Subgroup analyses showed MASH resolution rates remained significantly higher with semaglutide regardless of baseline diabetes status, though patients with type 2 diabetes had slightly lower absolute response rates. The safety profile was consistent with known GLP-1 agonist effects: gastrointestinal symptoms led to discontinuation in approximately 6% of semaglutide-treated patients.

How Semaglutide May Affect Liver Pathology

The mechanism by which semaglutide improves NASH involves at least three distinct pathways, only one of which depends on body weight reduction.

Weight-loss-mediated effects. Semaglutide-induced caloric deficit reduces visceral and hepatic adiposity. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) studies in patients receiving semaglutide show hepatic fat reductions of 50% to 70% from baseline, well beyond the 30% threshold associated with histological NASH improvement [8]. This reduction in hepatic triglyceride content decreases lipotoxic stress on hepatocytes.

Direct hepatocyte effects. GLP-1 receptors are expressed in human hepatocytes, and preclinical data from murine NASH models show that semaglutide reduces hepatic de novo lipogenesis through AMPK activation and SREBP-1c suppression independent of weight change [9]. Semaglutide also lowers hepatic expression of pro-inflammatory cytokines including TNF-alpha and IL-6, as demonstrated in paired biopsy transcriptomic analyses [10].

Systemic insulin sensitization. By improving peripheral insulin sensitivity and reducing hyperinsulinemia, semaglutide decreases the insulin-driven lipogenic drive that feeds hepatic steatosis. Fasting insulin levels fell by 35% in the ESSENCE semaglutide arm versus 8% with placebo [7]. This effect may be particularly relevant in patients with concurrent type 2 diabetes or insulin resistance.

The relative contribution of each pathway remains an open research question. Mediation analyses from the Newsome trial suggest that approximately 40% of the NASH resolution effect is independent of weight change [6], but this estimate carries wide confidence intervals.

GRADE Evidence Assessment

Applying the GRADE framework to the semaglutide-NASH evidence yields a moderate-quality (GRADE B) rating for the outcome of NASH resolution and a moderate-quality rating for fibrosis improvement [11].

The rating starts at high quality because both key studies are randomized controlled trials with blinding and biopsy-confirmed endpoints. One level is downgraded for indirectness: the phase 2 trial used daily dosing (0.4 mg/day, a total weekly exposure higher than the 2.4 mg/week Wegovy dose), while the phase 3 ESSENCE trial used the commercially available 2.4 mg weekly regimen. No downgrade is applied for inconsistency (both trials show the same direction of effect with overlapping confidence intervals), imprecision (sample sizes are adequate for the primary endpoints), or publication bias.

The 2023 AASLD Practice Guidance on metabolic dysfunction-associated steatotic liver disease states: "GLP-1 receptor agonists may be considered for patients with MASH, particularly those with coexisting type 2 diabetes or obesity, though they are not yet approved for this indication" [12]. The European Association for the Study of the Liver (EASL) issued a similar position in its 2021 clinical practice guidelines on drug treatment of NAFLD [13].

Semaglutide vs. Resmetirom (Rezdiffra): Different Mechanisms, Different Targets

In March 2024, the FDA approved resmetirom (Rezdiffra) as the first drug specifically indicated for NASH/MASH with moderate to advanced fibrosis (stages F2-F3) [14]. Resmetirom is a thyroid hormone receptor beta agonist that acts directly on hepatocytes to reduce liver fat and fibrosis through a mechanism entirely distinct from GLP-1 signaling.

In the MAESTRO-NASH trial (N=966), resmetirom 100 mg daily achieved NASH resolution in 30% of patients versus 10% placebo at 52 weeks, and fibrosis improvement of ≥1 stage in 26% versus 14% [15]. These absolute response rates are lower than those seen with semaglutide in ESSENCE, but cross-trial comparisons are unreliable because of differences in patient populations, trial duration (52 vs. 72 weeks), and placebo response rates.

A practical distinction: resmetirom targets the liver directly without meaningful weight loss, making it potentially suitable for lean MASH patients (BMI <30) who would not qualify for Wegovy under its approved indication. Semaglutide addresses both the hepatic and metabolic syndrome components of MASH but carries gastrointestinal side effects that resmetirom largely avoids. Some hepatologists now consider combination therapy, though no trial has tested resmetirom plus semaglutide together.

Practical Considerations for Off-Label Prescribing

Several clinical and logistical factors shape the decision to prescribe Wegovy off-label for NASH.

Insurance coverage. Most commercial payers and Medicare Part D plans cover Wegovy only for the FDA-approved weight management indication. A patient with NASH who also meets BMI criteria (≥30 or ≥27 with comorbidity) may obtain coverage through the obesity indication, but a patient with NASH and a normal BMI will face significant out-of-pocket cost. The list price for Wegovy is approximately $1,350 per month without insurance [16].

Dose titration. Wegovy uses a five-step dose escalation over 16 weeks (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg weekly) to reduce gastrointestinal intolerance [4]. Clinicians managing NASH patients should follow this same schedule. Skipping titration steps increases rates of nausea, vomiting, and early discontinuation.

Monitoring. Baseline and serial liver enzyme monitoring (ALT, AST, GGT) every 12 weeks is reasonable during the first year. AASLD guidance does not mandate repeat liver biopsy to assess treatment response outside of clinical trials, but noninvasive markers such as FIB-4 score and vibration-controlled transient elastography (FibroScan) can track fibrosis trajectory [12].

Duration of therapy. Neither the Newsome nor ESSENCE trials included post-treatment follow-up biopsies, leaving the durability of NASH resolution after semaglutide discontinuation unknown. Weight regain after GLP-1 agonist cessation is well documented (the STEP 1 extension trial showed two-thirds of lost weight was regained within one year of stopping [17]), and NASH recurrence could plausibly follow. Indefinite treatment may be necessary, which has cost implications.

Gallbladder events. Rapid weight loss with GLP-1 agonists increases the risk of cholelithiasis. In the SELECT trial, gallbladder-related events occurred in 2.8% of semaglutide-treated patients versus 2.3% on placebo [5]. Patients with pre-existing gallstone disease should be counseled about this risk.

Who Might Be a Candidate for Off-Label Wegovy in NASH

Not every NASH patient is an appropriate candidate for off-label semaglutide. The strongest evidence applies to patients who meet all of the following criteria: biopsy-confirmed or noninvasively diagnosed MASH with fibrosis stage F2 or F3 (matching the ESSENCE population), coexisting obesity or overweight (allowing potential insurance coverage via the weight management indication), and absence of decompensated cirrhosis or Child-Pugh B/C liver disease [7].

Patients who also have type 2 diabetes may derive additional benefit given the glucose-lowering properties of semaglutide. The ADA Standards of Care recommend GLP-1 receptor agonists as preferred second-line therapy in type 2 diabetes with obesity, and the presence of NASH adds a supporting rationale [18].

Patients with NASH and normal BMI (so-called lean NASH, affecting roughly 10% to 20% of the NASH population) present a more complex scenario. The ESSENCE trial included few patients with BMI <27, and the risk-benefit calculation for a drug that causes significant weight loss in already normal-weight individuals is less favorable [7]. Resmetirom or pioglitazone (which has its own evidence base in NASH [19]) may be more appropriate in this subgroup.

Dr. Mary Rinella, who chaired the AASLD-EASL nomenclature consensus, has noted: "We are entering an era where MASH treatment will require phenotyping. The right drug for each patient depends on their metabolic profile, fibrosis stage, and comorbidity burden, not a one-size approach" [20].

What the Evidence Does Not Yet Show

Two gaps in the current data deserve direct acknowledgment. First, no trial has demonstrated that semaglutide reduces hard liver outcomes: progression to cirrhosis, need for liver transplant, or liver-related mortality. The ESSENCE trial used histological surrogates (NASH resolution, fibrosis improvement), which are validated predictors of long-term outcomes but are not themselves clinical endpoints. A cardiovascular outcomes benefit was shown in SELECT, but a liver outcomes trial has not been completed [5].

Second, the relationship between semaglutide dose and liver histology is not fully defined. The phase 2 trial tested daily doses from 0.1 to 0.4 mg (roughly 0.7 to 2.8 mg weekly equivalent), while ESSENCE used 2.4 mg weekly [6][7]. Whether higher doses (such as the 7.2 mg weekly dose being studied as CagriSema for obesity) produce greater histological benefit is unknown. The ongoing SOUL trial examining cardiovascular and renal outcomes with oral semaglutide may provide additional liver-related safety data but is not designed to assess NASH endpoints [21].

Clinicians should frame off-label Wegovy for NASH as supported by moderate-quality evidence from two well-designed RCTs showing histological improvement at 72 weeks, while acknowledging the absence of long-term liver outcome data and the uncertain durability of benefit after discontinuation.